Entrada Therapeutics, Inc. — Director's Dealing 2021

Dec 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-12-29

Reporting Person: KREHER NERISSA (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-29	Common Stock	M	5200	$2.10	Acquired	5200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-29	Stock Option (Right to Buy)	$2.10	X	5200	Disposed	2030-12-01	Common Stock (5200)	Direct

Footnotes

F1: 25% of the shares subject to this option vested and became exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.